Physician

Michael Anthony Rihner, MD

According to 2025 Medicare claims, Michael Rihner, MD (NPI: 1831279702) practices cardiology in the Mobile, AL market, with the plurality of this provider's patient population coming from Mobile, AL. This provider's primary affiliated billing organization is RIHNER, GUPTA & GROSZ CARDIOLOGY, P.C. (NPI: 1548320716; TIN: 63-1205990) and primary practice location at 36695-9998.

Rihner's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 723 traditional Medicare patients, billed 4,504 HCPCS/CPT codes, and received $468,557 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 15,527 prescription claims across 1,396 beneficiaries totaling $2,388,175 in drug costs, led by Xarelto (Rivaroxaban). 2022 DME data shows 13 claims. Open Payments data shows 34 records totaling $580. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $534,651 to $2,388,175. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,501 to $308.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,057	19,658	$635,398
2016	1,152	19,408	$602,337
2017	1,080	12,311	$635,324
2018	1,053	8,690	$558,051
2019	1,027	7,858	$673,849
2020	969	6,676	$737,512
2021	894	5,812	$656,001
2022	853	5,915	$770,822
2023	812	4,923	$666,404
2024	723	4,504	$468,557

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	736	8,815	$534,651
2016	757	9,514	$605,079
2017	884	10,083	$642,937
2018	925	10,789	$795,149
2019	986	11,466	$971,597
2020	1,084	13,287	$1,225,316
2021	1,181	14,796	$1,600,813
2022	1,269	15,827	$2,130,040
2023	1,343	15,263	$2,301,843
2024	1,396	15,527	$2,388,175

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	61	$6,871
2016	11	113	$7,855
2017	12	119	$6,111
2018	N/R	52	$2,690
2019	N/R	23	$928
2020	N/R	42	$2,202
2021	N/R	41	$1,304
2022	N/R	13	$253
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	284	292	$117
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	154	235	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	454	1,005	$77
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	207	253	$11
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	382	433	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	559	31,433	$579,611
Entresto	Sacubitril/Valsartan	460	26,969	$568,442
Eliquis	Apixaban	251	12,620	$243,493
Mounjaro	Tirzepatide	157	5,124	$192,163
Farxiga	Dapagliflozin Propanediol	112	7,881	$145,182

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$580	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Anthony Rihner, MD?

Tedicare shows public-source Medicare data for Michael Anthony Rihner, MD (NPI 1831279702), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Anthony Rihner, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Anthony Rihner, MD?

Michael Anthony Rihner, MD is linked to RIHNER, GUPTA & GROSZ CARDIOLOGY, P.C. (billing NPI 1548320716) in the available physician profile data.

Does Michael Anthony Rihner, MD have Open Payments data?

Michael Anthony Rihner, MD has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.